Journal
ADVANCED HEALTHCARE MATERIALS
Volume 11, Issue 16, Pages -Publisher
WILEY
DOI: 10.1002/adhm.202201038
Keywords
cancer cell membranes; CRISPR-Cas9; gene therapy; gold nanoparticles; photothermal therapy
Funding
- National Key Research and Development Program of China [2018YFA0902702]
- National Natural Science Foundation of China [21890743, 32001006]
- Scientific Research of BSKY from Anhui Medical University [XJ201930]
Ask authors/readers for more resources
A cancer cell membrane-derived nanocarrier was developed for synergistic photothermal/gene therapy. This nanotherapeutic platform showed high biocompatibility, homologous targeting capacity, and efficient payload delivery, leading to enhanced therapeutic efficacy.
Bimodal synergistic therapy produces superadditive effect for enhanced therapeutic efficacy. However, how to efficiently and simultaneously deliver several kinds of therapeutic agents is still challenging. A cancer cell membrane-derived nanocarrier (mCas9-sGNRs) is proposed for synergistic photothermal/gene therapy (PTT/GT) by efficient delivery of clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated protein 9 (Cas9) and gold nanorods (GNRs). In this approach, Cas9 proteins can be efficiently loaded inside the cell membranes (mCas9) by electrostatic interactions. Similarly, single-guide RNAs, which target survivin, can be loaded onto GNRs (sGNRs) through electrostatic interactions and encapsulated by mCas9. As a result, the nanodelivery systems present advantages in biocompatibility, homologous targeting capacity and loading efficiency of cargoes. In addition, significant antitumor effects is achieved by gene editing of survivin which induces anticancer activity and reduces heat tolerance of cancer cells caused by GNRs mediated PTT due to the downregulation of HSP70. These results indicate the nanotherapeutic platform leads to enhanced PTT/GT efficacy. Therefore, this work not only provides a general strategy to construct a versatile nanoplatform for loading and target delivery of several therapeutic cargos but will also be valuable for PTT/GT and other bimodal synergistic therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available